The Role of TLRs in Anti-cancer Immunity and Tumor Rejection
Zuzanna Urban‐Wójciuk(University of Gdańsk), Mohd M. Khan(University of Maryland, Baltimore), Benjamin L. Oyler(University of Maryland, Baltimore), Robin Fåhræus(Masaryk Memorial Cancer Institute), Natalia Marek-Trzonkowska(Gdańsk Medical University), Aleksandra Nita‐Lazar(National Institutes of Health), Ted R. Hupp(MRC Institute of Genetics and Molecular Medicine), David R. Goodlett(University of Gdańsk)
Cited by 308Open Access
Abstract
In recent years, a lot of scientific interest has focused on cancer immunotherapy. Although chronic inflammation has been described as one of the hallmarks of cancer, acute inflammation can actually trigger the immune system to fight diseases, including cancer. Toll-like receptor (TLR) ligands have long been used as adjuvants for traditional vaccines and it seems they may also play a role enhancing efficiency of tumor immunotherapy. The aim of this perspective is to discuss the effects of TLR stimulation in cancer, expression of various TLRs in different types of tumors, and finally the role of TLRs in anti-cancer immunity and tumor rejection.
Related Papers
No related papers found
Powered by citation graph analysis